Member Info for Screech777

I think this will be a great multibagger by end of summer let’s see what next week brings.

NFX will surprise quite a few, obviously patience always needed and with a 65k holding I’m heavily loaded up. GLA - I look forward to newsflow

nice 9.5k buy at 4.10

https://patents.google.com/patent/US20130203806A1/en?assignee=nuformix&oq=nuformix

When you look at the price and trades around that time.Noticed a few decent buys showing as sells this week.

this morning expect see more later imo

Showing from yesterday

4.50p paid

why Such a bitter man coming across so desperate ! you sold too early and believed a placing was coming.You hoped to buy in cheaper and clearly missed the boat, at least try to be happy for others who kept the faith and are still holding.

Inner-Harmony AKA ‪@BlueHorselcf ‬on twitter not invested in NFX but constantly likes to spout negativity on here.Say no more and good luck to all the holders.We will let the news do the talking, lots to come

Inner-Harmonh appreciate your views but we know you aren’t invested so do you really need to waste your time on this board ? I thought weekends were family time for you

I honestly think with so much news to come this will see 20p by end of summer maybe sooner Small Mcap and small freefloat- “Chris presided over a period of significant growth including deal-making (including a $375m out-licensing agreement with Novartis, Europe's largest biotech deal of 2005), fund-raising, M&A and corporate development that transformed Vectura's capabilities from research led technology development to commercially driven pharmaceutical development. Chris' track record and experience will guide Nuformix through its next stage of growth.” I have no doubt that this will be the biggest share of the year - also my biggest holding, so happy days GLA

Definitely a buy and some nice buys today roll on news

Showing from the 4/5

Bring on the news

Lots of news due - looking forward to updates

Price holding up well I’m looking forward to news lots due and not much stock available - any good news will see a good increase in the SP

This is not aim lol this is the main market

2017, from macro forces and an unusually full M&A pipeline, is likely to push biopharma deal-making to new heights.” - Ernst & Young Jounce Therapeu+cs IPO Jan 2017 Immuno-oncology Phase 1 $555M Corvus Pharmaceu+cals IPO March 2016 Immuno-oncology Phase 1 $298M Argenx / AbbVie Strategic Alliance April 2016 Immuno-oncologyPreclinical $685M Delinia / Celgene Trade Sale Jan 2017 Immunotherapy Preclinical $775M EngMab / Switzerland Celgene Trade Sale Oct 2016 Immuno-oncology Preclinical $600M Tolero / Sumitomo Dainippon Trade Sale Jan 2017 Hematology oncology Phase 1 $780M Kolltan Pharmaceu+cals / Celldex Trade Sale Nov 2016 Immuno-oncology Phase 1 $235M http://www.hemogenyx-ir.com/archive/presentations/IPO-presentation.pdf?v=260118

DTL 8.41% in NKTN - DTL ‘Nigel Robertson Executive Chairman - the lead angel investor in asos.com which has gone on to become one of the world’s largest online fashion companies, operating in 197 countries. It is quoted on AIM with a market value of over £5.0bn.’ Plus Blue Star Capital are shareholders in DTL